Can the grading of mild cardiac allograft vasculopathy be further refined? An angiographic and physiologic assessment of heart transplant recipients with ISHLT CAV 1.

IF 6.4 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Journal of Heart and Lung Transplantation Pub Date : 2024-12-30 DOI:10.1016/j.healun.2024.12.013
Nikil Prasad, Erin Harris, Melana Yuzefpolskaya, Ersilia M DeFilippis, Paolo C Colombo, Gabriel Sayer, Margarita Chernovolenko, Justin Fried, David Bae, Kyung Taek Oh, Jayant Raikhelkar, Veli K Topkara, Michelle Castillo, Elaine Y Lam, Farhana Latif, Koji Takeda, Nir Uriel, Andrew J Einstein, Kevin J Clerkin
{"title":"Can the grading of mild cardiac allograft vasculopathy be further refined? An angiographic and physiologic assessment of heart transplant recipients with ISHLT CAV 1.","authors":"Nikil Prasad, Erin Harris, Melana Yuzefpolskaya, Ersilia M DeFilippis, Paolo C Colombo, Gabriel Sayer, Margarita Chernovolenko, Justin Fried, David Bae, Kyung Taek Oh, Jayant Raikhelkar, Veli K Topkara, Michelle Castillo, Elaine Y Lam, Farhana Latif, Koji Takeda, Nir Uriel, Andrew J Einstein, Kevin J Clerkin","doi":"10.1016/j.healun.2024.12.013","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cardiac allograft vasculopathy (CAV) results in impaired blood flow in both epicardial vessels and the microvasculature and is a leading cause of poor outcomes in heart transplant (HT) recipients. Most patients have mild (International Society for Heart and Lung Transplantation [ISHLT] CAV 1) disease. This study examined outcomes among those with ISHLT CAV 1 and investigated the value of physiologic assessment via cardiac positron emission tomography/computed tomography (PET/CT) for added risk stratification.</p><p><strong>Methods: </strong>CAV was graded using ISHLT criteria. Those with CAV 1 were further subgrouped into CAV 1a (maximal lesion <30% stenosis) or CAV 1b (maximal lesion ≥30% stenosis).</p><p><strong>Results: </strong>299 HT recipients underwent invasive coronary angiography for CAV assessment with a median follow-up of 4.7 years. ISHLT CAV 1 was associated with a 2.9-fold risk of death/retransplantation compared to ISHLT CAV 0 (95% confidence interval [CI] 1.7-5.3, p < 0.001). Of those with ISHLT CAV 1, 12% had ISHLT CAV 1b, which was associated with a 2.8 times greater risk of death/retransplantation compared to CAV 1a (95% CI 1.4-5.9, p = 0.003). In a subgroup of 158 patients with contemporary cardiac PET/CT, among those with CAV 1a, a myocardial blood flow reserve (MBFR) ≤2 was associated with a 4.6-fold risk of death/retransplantation compared to a normal MBFR (95% CI 1.7-12.6, p = 0.001).</p><p><strong>Conclusion: </strong>Patients with CAV 1b had worse outcomes than those with CAV 1a. Among those with CAV 1a, the poorer outcomes than ISHLT CAV 0 observed were predominantly associated with reduced MBFR. These data suggest additional anatomic classification and physiologic assessment can further risk stratify those with ISHLT CAV 1.</p>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Heart and Lung Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.healun.2024.12.013","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Cardiac allograft vasculopathy (CAV) results in impaired blood flow in both epicardial vessels and the microvasculature and is a leading cause of poor outcomes in heart transplant (HT) recipients. Most patients have mild (International Society for Heart and Lung Transplantation [ISHLT] CAV 1) disease. This study examined outcomes among those with ISHLT CAV 1 and investigated the value of physiologic assessment via cardiac positron emission tomography/computed tomography (PET/CT) for added risk stratification.

Methods: CAV was graded using ISHLT criteria. Those with CAV 1 were further subgrouped into CAV 1a (maximal lesion <30% stenosis) or CAV 1b (maximal lesion ≥30% stenosis).

Results: 299 HT recipients underwent invasive coronary angiography for CAV assessment with a median follow-up of 4.7 years. ISHLT CAV 1 was associated with a 2.9-fold risk of death/retransplantation compared to ISHLT CAV 0 (95% confidence interval [CI] 1.7-5.3, p < 0.001). Of those with ISHLT CAV 1, 12% had ISHLT CAV 1b, which was associated with a 2.8 times greater risk of death/retransplantation compared to CAV 1a (95% CI 1.4-5.9, p = 0.003). In a subgroup of 158 patients with contemporary cardiac PET/CT, among those with CAV 1a, a myocardial blood flow reserve (MBFR) ≤2 was associated with a 4.6-fold risk of death/retransplantation compared to a normal MBFR (95% CI 1.7-12.6, p = 0.001).

Conclusion: Patients with CAV 1b had worse outcomes than those with CAV 1a. Among those with CAV 1a, the poorer outcomes than ISHLT CAV 0 observed were predominantly associated with reduced MBFR. These data suggest additional anatomic classification and physiologic assessment can further risk stratify those with ISHLT CAV 1.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
轻度同种异体心脏移植血管病变的分级能否进一步细化?心脏移植受者的血管造影和生理评估与ISHLT CAV 1。
背景:同种异体心脏移植血管病变(CAV)导致心外膜血管和微血管血流受损,是心脏移植(HT)受者预后不良的主要原因。大多数患者为轻度(轻度)CAV - 1疾病。本研究检查了那些患有ISHLT CAV 1的患者的结果,并研究了通过心脏正电子发射断层扫描/计算机断层扫描(PET/CT)进行生理评估的价值,以增加风险分层。方法:采用ISHLT标准对CAV进行分级。CAV 1患者进一步亚分组为CAV 1a(最大病变< 30%狭窄)或CAV 1b(最大病变≥30%狭窄)。结果:299名心脏移植受者接受有创冠状动脉造影评估CAV,中位随访4.7年。与ISHLT CAV 0相比,ISHLT CAV 1与死亡/再移植风险相关2.9倍(95% CI 1.7 -5.3, p)。结论:ISHLT CAV 1患者的预后比ISHLT CAV 0患者差。在ISHLT CAV 1中,CAV 1b患者的预后比CAV 1a患者差。在CAV 1a患者中,观察到的比ISHLT CAV 0患者更差的结果主要与MBFR降低有关。这些数据表明,额外的解剖分类和生理学评估可以进一步对ISHLT CAV - 1患者进行风险分层。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
10.10
自引率
6.70%
发文量
1667
审稿时长
69 days
期刊介绍: The Journal of Heart and Lung Transplantation, the official publication of the International Society for Heart and Lung Transplantation, brings readers essential scholarly and timely information in the field of cardio-pulmonary transplantation, mechanical and biological support of the failing heart, advanced lung disease (including pulmonary vascular disease) and cell replacement therapy. Importantly, the journal also serves as a medium of communication of pre-clinical sciences in all these rapidly expanding areas.
期刊最新文献
Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials. Vintage vitality: Embracing older donor lungs for transplants. A perspective on the added value of red blood cells during cardiac hypothermic oxygenated perfusion. Loss of Nr4a1 ameliorates endothelial cell injury and vascular leakage in lung transplantation from circulatory-death donor. Early stroke following durable left ventricular assist device (LVAD) implantation: An analysis of the Society of Thoracic Surgeons Intermacs National Database.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1